Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC..
Breast cancer is the most common malignancy in women worldwide and a highly heterogeneous disease. Four different subtypes are described that differ in the expression of hormone receptors as well as the growth factor receptor HER2. Treatment modalities and survival rate depend on the subtype of breast cancer. However, it is still not clear which patients benefit from immunotherapeutic approaches such as checkpoint blockade. Thus, we aimed to decipher the immune cell signature of the different breast cancer subtypes based on high-dimensional flow cytometry followed by unbiased approaches. Here, we show that the frequency of NK cells is reduced in Luminal A and B as well as triple negative breast cancer and that the phenotype of residual NK cells is changed toward regulatory CD11b-CD16- NK cells. Further, we found higher frequencies of PD-1+ CD4+ and CD8+ T cells in triple negative breast cancer. Moreover, while Luminal A-type breast cancer was enriched for CD14+ cDC2 (named type 3 DC (DC3)), CD14- cDC2 (named DC2) were more frequent in triple negative breast cancer. In contrast, HER2-enriched breast cancer did not show major alterations in the composition of the immune cell compartment in the tumor microenvironment. These findings suggest that patients with Luminal A- and B-type as well as triple negative breast cancer might benefit from immunotherapeutic approaches targeting NK cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Oncoimmunology - 13(2024), 1 vom: 04., Seite 2296713 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Heger, Lukas [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Breast cancer |
|---|
| Anmerkungen: |
Date Completed 05.01.2024 Date Revised 05.01.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1080/2162402X.2023.2296713 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366607812 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366607812 | ||
| 003 | DE-627 | ||
| 005 | 20240108142303.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240108s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/2162402X.2023.2296713 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1249.xml |
| 035 | |a (DE-627)NLM366607812 | ||
| 035 | |a (NLM)38170155 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Heger, Lukas |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Unbiased high-dimensional flow cytometry identified NK and DC immune cell signature in Luminal A-type and triple negative breast cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.01.2024 | ||
| 500 | |a Date Revised 05.01.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. | ||
| 520 | |a Breast cancer is the most common malignancy in women worldwide and a highly heterogeneous disease. Four different subtypes are described that differ in the expression of hormone receptors as well as the growth factor receptor HER2. Treatment modalities and survival rate depend on the subtype of breast cancer. However, it is still not clear which patients benefit from immunotherapeutic approaches such as checkpoint blockade. Thus, we aimed to decipher the immune cell signature of the different breast cancer subtypes based on high-dimensional flow cytometry followed by unbiased approaches. Here, we show that the frequency of NK cells is reduced in Luminal A and B as well as triple negative breast cancer and that the phenotype of residual NK cells is changed toward regulatory CD11b-CD16- NK cells. Further, we found higher frequencies of PD-1+ CD4+ and CD8+ T cells in triple negative breast cancer. Moreover, while Luminal A-type breast cancer was enriched for CD14+ cDC2 (named type 3 DC (DC3)), CD14- cDC2 (named DC2) were more frequent in triple negative breast cancer. In contrast, HER2-enriched breast cancer did not show major alterations in the composition of the immune cell compartment in the tumor microenvironment. These findings suggest that patients with Luminal A- and B-type as well as triple negative breast cancer might benefit from immunotherapeutic approaches targeting NK cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a NK cells | |
| 650 | 4 | |a PD-1 | |
| 650 | 4 | |a immune cell signature | |
| 650 | 4 | |a tumor microenvironment | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Heidkamp, Gordon F |e verfasserin |4 aut | |
| 700 | 1 | |a Amon, Lukas |e verfasserin |4 aut | |
| 700 | 1 | |a Nimmerjahn, Falk |e verfasserin |4 aut | |
| 700 | 1 | |a Bäuerle, Tobias |e verfasserin |4 aut | |
| 700 | 1 | |a Maier, Andreas |e verfasserin |4 aut | |
| 700 | 1 | |a Erber, Ramona |e verfasserin |4 aut | |
| 700 | 1 | |a Hartmann, Arndt |e verfasserin |4 aut | |
| 700 | 1 | |a Hack, Carolin C |e verfasserin |4 aut | |
| 700 | 1 | |a Ruebner, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Huebner, Hanna |e verfasserin |4 aut | |
| 700 | 1 | |a Fasching, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Beckmann, Matthias W |e verfasserin |4 aut | |
| 700 | 1 | |a Dudziak, Diana |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncoimmunology |d 2012 |g 13(2024), 1 vom: 04., Seite 2296713 |w (DE-627)NLM218817029 |x 2162-402X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:1 |g day:04 |g pages:2296713 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/2162402X.2023.2296713 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 1 |b 04 |h 2296713 | ||